OraSure Technologies, Inc.
OSUR Healthcare Medical Instruments & Supplies
OraSure Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $115.0 million, down 38.1% from fiscal 2024. In the quarter to June 2026, revenue fell 1.93%, EPS grew 134.6%, free cash flow fell 1.40% and total debt fell 8.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OSUR
OraSure Technologies, Inc. (OSUR) EV/Sales
As of 16 October 2026, OraSure Technologies, Inc. (OSUR) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from −0.5× (November 2025) to 8.3× (September 2017); the current reading is higher than 31% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.2× | — |
| FY2024 | 0.0× | (99.27%) |
| FY2023 | 0.8× | 27.91% |
| FY2022 | 0.6× | (69.88%) |
| FY2021 | 2.0× | (31.15%) |
| FY2020 | 2.9× | 33.98% |
| FY2019 | 2.2× | (28.21%) |
| FY2018 | 3.1× | (47.90%) |
| FY2017 | 5.9× | 105.07% |
| FY2016 | 2.9× | 31.20% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.3× | 359.75% |
| Mar 2026 | 0.3× | — |
| Dec 2025 | −0.2× | — |
| Sep 2025 | 0.1× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NNNN Anbio Biotechnology compare | n/m |
| ZJYL Jin Medical International Ltd. compare | n/m |
| OSUR OraSure Technologies, Inc. | 0.8× |
| ANGO AngioDynamics, Inc. compare | 1.5× |
| EMBC Embecta Corp. compare | 1.6× |
| PDEX Pro-Dex, Inc. compare | 2.5× |
| KRMD KORU Medical Systems, Inc. compare | 2.9× |
| SMTI Sanara MedTech Inc. compare | 2.9× |
| UTMD Utah Medical Products, Inc. compare | 4.2× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)